JP2004506605A5 - - Google Patents

Claims (11)

A composition for achieving synergy to treat insulin resistance in a mammal in need thereof, comprising an effective amount of (a) a choline base or a pharmaceutically acceptable salt thereof; and (b) succinic acid Or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier, wherein (a) the amount of component alone and (b) the amount of component alone is insufficient to achieve its action. Yes; and wherein the effect of the total amount of components (a) and (b) is greater than the total effect achievable using the individually administered amounts of components (a) and (b). The composition of claim 1, wherein the action includes reducing plasma insulin levels. A composition for achieving synergy to treat diabetes mellitus in a mammal in need thereof, wherein said mammal has an effective amount of (a) a choline base or a pharmaceutically acceptable salt thereof; and (b) Succinic acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier, wherein the amount of component (a) alone and the amount of component (b) alone are not sufficient to achieve the action. A composition as described above, which is sufficient; and wherein the effect of the total amount of components (a) and (b) is greater than the total effect achievable using the amounts of components (a) and (b) administered individually. 4. The composition of claim 3, wherein the effect includes lowering plasma glucose levels. The composition according to any one of claims 1 to 4, wherein the pharmaceutically acceptable salt of choline is choline chloride. The composition according to any one of claims 1 to 5, wherein the pharmaceutically acceptable salt of succinic acid is disodium succinate. The composition according to any one of claims 1 to 6, wherein the effective amount of choline base or a pharmaceutically acceptable salt thereof is 3 to 300 mg per kg of body weight of a mammal per day. The composition according to any one of claims 1 to 7, wherein the effective amount of succinic acid or a pharmaceutically acceptable salt thereof is 1 to 250 mg per kg body weight of a mammal per day. A composition comprising bis (2-hydroxy-N, N, N-trimethylethanaminium) succinate. A process for producing bis (2-hydroxy-N, N, N-trimethylethanaminium) succinate comprising reacting a choline base with succinic acid. 11. The method of claim 10, wherein the molar ratio of choline base to succinic acid is about 2: 1 but not lower than 1.9: 1 and not higher than 2.1: 1.